R&D Pipeline

We are constantly developing our platform to create new functional possibilities and areas of service.  We are continuously developing, broadening and refining the services we provide. Our aim is to continue being the most reliable and efficient provider of preclinical testing within immunology and immunotoxicity. We strive to develop even better solutions for evaluating investigational products with regard to their safety profile in human circulation. Development projects in pipeline:

B-cell malignancy model for safety and function

Testing a drug in patient-volunteers often results in “new knowledge”. We are looking into the benefits and the clinical relevance of testing drug-blood interactions in the target patient group already in the preclinical phase.

Receptor occupancy

What parameters guide the selection of a safe starting dose? We are determining receptor occupancy and using it as one parameter to define the minimal anticipated biological effect level (MABEL) as the basis for calculating safer starting doses for first-in-man trials.

Autoimmune responses: multiple sclerosis, a model for safety and function

We are developing a disease-specific model for testing drug-blood interactions in fresh, circulating blood from patients with multiple sclerosis.
I can only recommend Immuneed. We performed a PBMC proliferation study and they delivered high-quality data and the report in a timely manner.
Associate Director, Immunotoxicology – Non-Clinical Safety, Non-Clinical Development & Bioanalysis
Ascendis Pharma
With Immuneed’s ID.Flow, a single platform gives us multiple readouts which provide us with a solid understanding of cytokines, complement, and drug biodistribution.
Prinicpal Scientist at Bioarctic Neuroscience
Bioarctic
Immuneed is a highly appreciated partner and has very short and flexible lead times, usually around 5 weeks. Adding the high sensitivity and reproducibility of the loop in assessing cytokine release and cell activation, we have chosen to use it as a routine in our preclinical development.
Director of Translational Medicine
Affibody